Citations

Clear

4564 citation(s) found for "Yu, Virginia".

Access Options for Transcatheter Aortic Valve Replacement
Chidester, Jeffrey , Donisan, Teodora , Desai, Parth , Banthiya, Sukriti , Zaghloul, Ahmed , Jessen, Michael E. , Tan, Weiyi , Huffman, Lynn C., Bavry, Anthony A. , Desai, Parth V , Bavry, Anthony A , Zaghloul, Ahmed, Park, Ki E. , Tsai, Shirling X. , Kumbhani, Dharam J. , Goyal, Amit

Mayo Clinic

Journal of Clinical Medicine | February 28, 2025 | Volume: 14 | Issue: 5 | Pages: 1651

10.3390/jcm14051651 | PMID 40095640 Get It

Transcatheter aortic valve replacement (TAVR) was introduced in 2002 and has become integral in the management of aortic stenosis. As an alternative to surgical aortic valve replacement, it relies heavily on safe access to the aortic annulus for implantation of a valve prosthesis. Throughout its development and in current practice, the transfemoral (TF) arterial route for retrograde valve delivery has been the primary approach. However, this route is not appropriate for all patients, which has led to the development of multiple alternate access options. This review discusses the development of access for TAVR, followed by a thorough discussion of TF access. The commercially available products, preprocedural planning, closure techniques, and procedural complications are all discussed. We also describe the various alternate access routes with particular emphasis on the most recently developed route, transcaval access (TCv), with focus on procedural indications, technical considerations, and comparative outcomes. As TAVR technology, indications, and availability all expand, the knowledge and implementation of safe access are of utmost importance.
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
Riner, Andrea N. , Rajpara, Seeta , Qian, Jing , Jin, Yuxin , Loza, Donna, Akki, Ashwin , Raj, Rohit , Merchant, Nipun B. , Hughes, Steven , Reams, Renee, Redda, Ken, Odedina, Folakemi T., Agyare, Edward , Craig, David W. , Carpten, John D. , Trevino, Jose , Velazquez‐Villarreal, Enrique , Herremans, Kelly M. , Williams, Terence M. , George, Thomas J. , Hughes, Steven J., Stern, Mariana Carla , Redda, Ken, Wilkie, Diana J. , Chamala, Srikar , Han, Bo

Mayo Clinic

Pancreas | February 25, 2025 | Volume: 54 | Issue: 3 | Pages: e171-e178

10.1097/mpa.0000000000002408 | PMID 39999309 Get It

Objectives Black/African American (B/AA) pancreatic ductal adenocarcinoma (PDAC) patients have worse clinical outcomes than White patients and are underrepresented in genomic databases. We aimed to expand our understanding of the PDAC somatic landscape from a diverse cohort. Materials and Methods Formalin-fixed paraffin-embedded specimens from 24 surgically resected PDAC cases were collected, with self-reported race/ethnicity. Whole exome sequencing was performed on malignant and benign tissue. Bioinformatics analysis included deduction of genetic ancestry and somatic mutational analysis, with comparisons to public datasets. Results Out of 24 cases, 17 identified as B/AA race; genetic ancestry analysis confirmed proportions of Sub-Saharan African ancestry greater than 47%. The most commonly mutated genes included KRAS , TP53 , SMAD4 , and CDKN2A . Comparison of mutations in our cohort versus publicly available, predominantly White datasets showed higher mutation frequencies of ATM, RREB1, BRCA1/2, KDM6A, ARID1A, BRAF, and MYC ( P < 0.04). When cohorts were combined and analyzed by race, no mutation frequencies differences were observed, including KRAS . Conclusions Genomic analysis of PDAC tumors from B/AA and White patients demonstrate similarities in mutation frequencies. Larger studies are needed to further understand molecular characterizations across continental subpopulations. This study provides further rationale for equitable representation of diverse patients in genomic databases and clinical trials.
Exercise-based cardiac rehabilitation in patients with left ventricular assist devices: an updated systematic review and meta-analysis of randomized controlled trials
Abuelazm, Mohamed , Amin, Ahmed Mazen , Abdelgalil, Mahmoud Shaaban , Khan, Ubaid , Rezq, Hazem , Elbenawi, Hossam , Turkmani, Mustafa , Abdelazeem, Basel , Shaaban Abdelgalil, Mahmoud , Turkmani, Mustafa , Abdelazeem, Basel , Abuelazm, Mohamed , Ibrahim, Ahmed Abdelmoniem , Bianco, Christopher Michael , Balla, Sudarshan

Mayo Clinic

Expert Review of Medical Devices | February 19, 2025 | Volume: 22 | Issue: 3 | Pages: 219-232

10.1080/17434440.2025.2468788 | PMID 39968882 Get It

Intravenous Thrombolysis in Cervical Artery Dissection–Related Stroke: A Nationwide Study
Shu, Liqi , Lee, Elizabeth , Field, Thalia S. , Guo, Xiaofan , Henninger, Nils , Keser, Zafer , Khan, Muhib , Mistry, Eva , Nguyen, Thanh N. , Siegler, James E. , Strelecky, Lukas , Furie, Karen L. , Mistry, Eva A , Mandel, Daniel M , Stretz, Christoph , Furie, Karen L , Yaghi, Shadi , Field, Thalia S , Keser, Zafer , Nguyen, Thanh N , Siegler, James E , Henninger, Nils , Guo, Xiaofan , Lee, Elizabeth , Mandel, Daniel , Stretz, Christoph , Yaghi, Shadi

Mayo Clinic

Journal of the American Heart Association | February 19, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.039662 | PMID 39968775 Get It

Background Although intravenous thrombolysis (IVT) is safe and effective in populations with general stroke, its impact on cervical artery dissection–related acute ischemic stroke (CeAD‐AIS) remains unclear. This retrospective study used the National Inpatient Sample to compare outcomes in patients with CeAD‐AIS treated with and without IVT. Methods We included adult patients with concurrent CeAD and AIS diagnoses ( International Classification of Diseases, Tenth Revision [ ICD‐10 ], codes) hospitalized from 2016 to 2019. The primary outcome was home discharge; safety outcomes included inpatient death and intracerebral hemorrhage. We performed survey‐weighted multivariable logistic regressions comparing IVT versus no IVT, followed by interaction analyses to examine effect modifications based on age, medical history, stroke severity, carotid artery involvement, and endovascular treatment. Results Between 2016 and 2019, 1360 (12.1%) of 11 285 patients with CeAD‐AIS received IVT. IVT‐treated patients had higher median National Institutes of Health Stroke Scale scores (median [interquartile range], 8 [4–17] versus 3 [1–11]; P <0.001). Adjusted analyses showed IVT was associated with higher odds of home discharge (adjusted odds ratio [OR], 1.40 [95% CI, 1.01–1.92]; P =0.042), but not with inpatient death (adjusted OR, 1.29 [95% CI, 0.76–2.20]; P =0.347) or intracerebral hemorrhage (adjusted OR, 0.69 [95% CI, 0.32–1.48]; P =0.341). Stroke severity ( P for interaction=0.001) and carotid artery involvement ( P for interaction=0.021) significantly modified IVT's effect on home discharge, with IVT being associated with an increased likelihood of home discharge in patients with moderate to severe strokes (National Institutes of Health Stroke Scale score >4) and carotid artery involvement. Conclusions IVT improves the likelihood of home discharge in patients with CeAD‐AIS without increasing the risk of inpatient death or intracerebral hemorrhage.
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
Idalsoaga, Francisco , Díaz, Luis Antonio , Guizzetti, Leonardo , Dunn, Winston , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Mahli, Gurpreet, Islam, Alvi H. , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Higuera‐de‐la‐Tijera, Fátima , Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García‐Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Elfeki, Mohamed A , Ramirez-Cadiz, Carolina , Cabezas, Joaquín , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Abraldes, Juan G , Jalal, Prasun K , García-Tsao, Guadalupe , Skladaný, Lubomir , Havaj, Daniel J , Kamath, Patrick S , Arrese, Marco , Bataller, Ramon A , Arab, Juan P , Guizzetti, L , Díaz, Luis A , Dunn, Winston , Echavaría, Victor , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Cabezas, Joaquín , Ventura‐Cots, Meritxell , Abraldeṣ, Juan G. , García–Tsao, Guadalupe , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 8 | Pages: 1391-1395

10.1111/apt.70024 | PMID 39967231 Get It

ABSTRACTSeveral dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH
Younossi, Zobair M. , Sherman, Michael S., Anstee, Quentin M. , Cusi, Kenneth , Lazarus, Jeffrey V. , Schuppan, Detlef, Schattenberg, Jörn M. , Vos, Miriam B. , Anstee, Quentin M , Cusi, Kenneth , Lazarus, Jeffrey V , Schuppan, Detlef , Romero-Gómez, Manuel , Wong, Vincent Wai-Sun , Sanyal, A J , Loomba, Rohit , Schattenberg, Jörn M , Razavi, Homie , Sherman, Michael, Allen, Alina M. , Friedman, Scott L. , Lawitz, Eric , Wong, Vincent Wai‐Sun , Ratziu, Vlad , Hompesch, Marcus , Sanyal, Arun J. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 9 | Pages: 1467-1478

10.1111/apt.70020 | PMID 39967239 Get It

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well‐being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non‐invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD‐related problem. Aim The aim of this article was to summarise the global burden of MASLD from the payer's perspective. Methods We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient‐reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively. Conclusion The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. Trial Registration: NCT06309992
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Pal, Sumanta K. , Loriot, Yohann , Necchi, Andrea , Singh, Parminder , Castellano, Daniel , Pagliaro, Lance C. , Suárez, Cristina , McGregor, Bradley A. , Vaishampayan, Ulka N. , Hauke, Ralph J. , Herpen, Carla M.L. van , Sudhagoni, Ramu, Schwickart, Martin, Andrianova, Svetlana, Powles, Thomas , Van Herpen, Carla M L , Courtney, Kevin D , Dreicer, Robert , Agarwal, Archana M , Necchi, Andrea , McGregor, Bradley , Vaishampayan, Ulka , Loriot, Yohann , Singh, Parminder , Dreicer, Robert , Agarwal, Neeraj

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 14 | Pages: 1650-1662

10.1200/jco-24-01675 | PMID 39965176 Get It

PURPOSE The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC). METHODS This phase Ib study (ClinicalTrials.gov identifier: NCT03170960 ) enrolled patients with inoperable locally advanced/metastatic UC into four tumor cohorts: first-line cisplatin-eligible (cis-eligible), first-line cisplatin-ineligible (cis-ineligible), previous platinum-containing chemotherapy (previous chemotherapy-treated), and previous immune checkpoint inhibitor (ICI)–treated. Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator per RECIST v1.1 every 6 weeks for 12 months and every 12 weeks thereafter; the secondary end point was safety. RESULTS A total of 121 patients (previous ICI-treated cohort, n = 31, and each of the other cohorts, n = 30) received study treatment from March 2018 to November 2021. The ORR (95% CI) was 30% (15 to 49) for cis-eligible, 20% (8 to 39) for cis-ineligible, 27% (12 to 46) for previous chemotherapy-treated, and 10% (2 to 26) for previous ICI-treated cohorts. The median progression-free survival (95% CI) was 5.5 (1.6 to 11.6), 5.6 (3.1 to 11.1), 5.4 (1.6 to 7.6), and 3.0 (1.8 to 5.5) months, respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) were experienced by 43%, 67%, 57%, and 45% of patients, respectively. TRAEs led to discontinuation of all treatment components in 17%, 13%, 3%, and 19%, respectively. No grade 5 TRAEs were reported in any cohort. CONCLUSION The novel combination of cabozantinib plus atezolizumab exhibited clinical activity in advanced UC that is cis-eligible, cis-ineligible, or previously treated with platinum-containing chemotherapy; clinical activity in previous ICI-treated UC was modest. The toxicity profile was consistent with that previously reported for the combination.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Hansen, Doris K. , Peres, Lauren C. , Dima, Danai , Richards, Alicia, Shune, Leyla , Afrough, Aimaz , Midha, Shonali , Dhakal, Binod , Kocoglu, Mehmet H. , Atrash, Shebli , Ferreri, Christopher, Davis, James A. , Bhurtel, Jenny , Wagner, Charlotte B , Bansal, Radhika , Smith, Kinaya, Avila, Gabriel De, Purvey, Sneha , Hosoya, Hitomi , Mikkilineni, Lekha , Oswald, Laura B. , Gaballa, Mahmoud , Forsberg, Peter A. , Janakiram, Murali , Htut, Myo , Maringanti, Sireesha Asoori, Kalariya, Nilesh, Hashmi, Hamza , Sborov, Douglas W. , Khouri, Jack , Raza, Shahzad , Atanackovic, Djordje , Alsina, Melissa , Freeman, Ciara Louise , Voorhees, Peter M. , Anderson, Larry D. , Martin, Thomas, Patel, Krina K. , Sidana, Surbhi , Castaneda Puglianini, Omar , Davis, James A , Bhurtel, Evguenia , McGuirk, Joseph , Wagner, Charlotte , Bansal, Radhika , Lieberman-Cribbin, Alex , De Avila, Gabriel , Purvey, Sneha , Hosoya, Hitomi , Kaur, Gurbakhash , Herr, Megan M. , Janakiram, Murali , Reshef, Ran , Sborov, Douglas W , Anwer, Faiz , Khouri, Jack , Alsina, Melissa , Locke, Frederick L , Voorhees, Peter , Anderson, Larry D , Lin, Yi , Patel, Krina , Sidana, Surbhi , Dima, Danai , Kocoglu, Mehmet H , Raza, Shahzad , Atrash, Shebli , Hansen, Doris K , Dhakal, Binod , Puglianini, Omar Castañeda , McGuirk, Joseph P. , Costello, Patrick , Kaur, Gurbakhash , Pasvolsky, Oren , Reshef, Ran , Nadeem, Omar , Anwer, Faiz , Locke, Frederick L. , Richard, Shambavi , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 13 | Pages: 1597-1609

10.1200/jco-24-01730 | PMID 39965175 Get It

PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell–associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.
Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)
Robbins, Eric , Bradley, Kaitlin, Badesch, David B., Burger, Charles D. , Chybowski, Amy, Marco, Teresa De , Hemnes, Anna R. , Mathai, Stephen C. , Melendres‐Groves, Lana , Sager, Jeffrey S., Shlobin, Oksana A. , Thenappan, Thenappan , Zamanian, Roham T. , Runo, James , Baird, Grayson L. , Robbins, Eric W , Burger, Charles , Mathai, Stephen C , Raza, Farhan , Shlobin, Oksana , Thenappan, Thenappan , Zamanian, Roham , Baird, Grayson L , Ventetuolo, Corey E , Hemnes, Anna , Lammi, Matthew R. , Raza, Farhan , Ventetuolo, Corey E.

Mayo Clinic

Annals of the American Thoracic Society | February 18, 2025 | Volume: 22 | Issue: 6 | Pages: 830-837

10.1513/annalsats.202312-1083oc | PMID 39965160 Get It

Abstract Rationale Pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. The extent of medication nonadherence in PAH is uncertain and may be linked to adverse outcomes. There has been a lack of multicenter, registry-based studies assessing medication nonadherence and patient-centered outcomes in PAH. Objectives To determine the prevalence of self-reported nonadherence in Pulmonary Hypertension Association Registry (PHAR) participants with PAH or chronic thromboembolic pulmonary hypertension and the relationship of nonadherence with several patient-centered outcomes (mortality, hospitalization rates, emergency department visits, and health-related quality of life). Methods Self-reported PAH medication nonadherence was captured at PHAR enrollment and during follow-up visits. Predictors of nonadherence were modeled using generalized estimating equations assuming a binary distribution. Outcomes associated with nonadherence were modeled using generalized estimating equations with a Poisson distribution. Results A total of 1,543 patients were included, of whom 1,092 (70.8%) were female and 1,340 (86.8%) had PAH. The overall rate of any self-reported nonadherence was 6.1% (95% confidence interval [CI], 5.3–6.9). Predictors of nonadherence included self-reported male sex at birth (odds ratio [OR], 1.4; 95% CI, 1.0–1.9; P = 0.02), poverty (OR, 1.6; 95% CI, 1.2–2.3; P = 0.01), not being married or partnered (OR, 1.5; 95% CI, 1.1–1.9; P = 0.01), having Medicaid or no health insurance (OR, 2.1; 95% CI, 1.5–2.9; P &lt; 0.001), and having completed high school but not having a college degree (OR, 1.7; 95% CI, 1.1–2.9; P &lt; 0.001). PHAR participants who reported any nonadherence had 50.0% more emergency department visits (P &lt; 0.001), 13.3% more hospital admissions (P = 0.03), and 61.9% more days hospitalized (P = 0.01). No relationship was observed between nonadherence and the type or number of PAH therapies or all-cause mortality. Participants reporting nonadherence had worse mean Short Form-12 scores (P &lt; 0.001) and worse emPHasis-10 scores (P = 0.02). Conclusions The rate of self-reported nonadherence in PHAR registrants was low but was associated with male sex and several social determinants of health. Although the complexity or type of PAH regimen did not appear to influence nonadherence, nonadherence was associated with numerous adverse patient-centered outcomes, including greater healthcare use and worse health-related quality of life. Because of limitations in the structure of the gathered data, relationships between exposure and outcomes were not temporally definitive; these observations warrant additional prospective studies.